title: Outcomes of haploidentical transplant compared with matched donor allogeneic stem cell transplant.
abstract: The risk of acute and chronic graft-versus-host disease (GVHD) with haploidentical transplant with post-transplant high-dose cyclophosphamide may be lower compared with matched unrelated donor transplant and largely similar to matched related donor transplant. The lower probability of GVHD with the haploidentical donor may result in a risk of nonrelapse mortality that is at least similar to or even lower than the matched donor. The incidence of relapse and survival are also largely similar to different donor types. Haploidentical transplant may be associated with slower engraftment. Given a lower risk of GVHD, haploidentical transplant has gained popularity. Additionally, the use of post-transplant high-dose cyclophosphamide has been extended to lower the risk of GVHD with matched donor and mismatched unrelated donor transplant.
authors.affiliation: Department of Medicine, Kathmandu University School of Medical Sciences, Dhulikhel, Kavre, Nepal.
authors.forename: Janak
authors.initials: J
authors.lastname: Adhikari
authors.affiliation: Department of Hematology-Oncology, Nobel Hospital, Kathmandu, Nepal.
authors.forename: Bishal
authors.initials: B
authors.lastname: Gyawali
authors.affiliation: Department of Medicine, Kathmandu University School of Medical Sciences, Dhulikhel, Kavre, Nepal.
authors.forename: Priyadarshani
authors.initials: P
authors.lastname: Sharma
authors.affiliation: Department of Internal Medicine, Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE 68198, USA.
authors.forename: Vijaya Raj
authors.initials: VR
authors.lastname: Bhatt
mesh_terms: D006084:Graft Rejection; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000209:etiology / Q000517:prevention & control / Q000628:therapy; D006680:HLA Antigens / Q000235:genetics* / Q000276:immunology; D006239:Haplotypes; D019337:Hematologic Neoplasms / Q000150:complications / Q000175:diagnosis / Q000401:mortality / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods; D006801:Humans; D009026:Mortality; D011183:Postoperative Complications; D012008:Recurrence; D012307:Risk Factors; D014019:Tissue Donors; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D014775:Virus Activation / Q000276:immunology; D014777:Virus Diseases / Q000209:etiology
chemical_list: D006680:HLA Antigens
keywords: allogeneic hematopoietic cell transplantation; donor source; engraftment; graft-versus-host disease; haploidentical hematopoietic cell transplantation; infection; matched hematopoietic cell transplantation; nonrelapse mortality; relapse; survival